The stock of Chromadex Corp (NASDAQ:CDXC) is a huge mover today! About 86,022 shares traded hands. Chromadex Corp (NASDAQ:CDXC) has declined 39.77% since April 27, 2016 and is downtrending. It has underperformed by 44.99% the S&P500.
The move comes after 9 months negative chart setup for the $91.40 million company. It was reported on Nov, 30 by Barchart.com. We have $2.33 PT which if reached, will make NASDAQ:CDXC worth $3.66M less.
Analysts await Chromadex Corp (NASDAQ:CDXC) to report earnings on March, 16.
According to Zacks Investment Research, “ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex’s core business strategy is to use the intellectual property harnessed by its expertise in the area of natural products and in the creation of reference materials to the industry as the basis for providing new and alternative, green, mass marketable products to its customers. The Company’s main priority is to create industry-accepted information, and to provide products and services to every layer of the functional food, pharmaceutical, personal care and dietary supplement markets. The company markets and sells its products in the United States and Canada. It offers its products through distributors in Europe, South America, Korea, India, Japan, Australia, New Zealand, China, Indonesia, Malaysia, Singapore, Thailand, and Mexico.”
More news for Chromadex Corp (NASDAQ:CDXC) were recently published by: Globenewswire.com, which released: “ChromaDex Launches New Patented Ingredient – IMMULINA(TM) – a Powerful …” on September 10, 2015. Globenewswire.com‘s article titled: “ChromaDex and Collaborators Report Unexpected Discovery of Novel Biomarkers of …” and published on August 12, 2015 is yet another important article.
CDXC Company Profile
Chromadex Corporation, incorporated on June 19, 2008, and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control services and products to the natural products industry. The Firm allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The Firm operates through three divisions: Ingredients, Core standards and contract services, and Scientific and regulatory consulting. Ingredients segment develops and commercializes ingredient technologies and supplies these ingredients to the manufacturers of consumer products in various industries, including the nutritional supplement, food and beverage, and animal health industries. Core standards and contract services segment includes supply of phytochemical reference standards, which are small quantities of plant compounds used to research an array of attributes, reference materials and related contract services. Scientific and regulatory consulting segment provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage health and regulatory risks.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.